A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease |
| |
Authors: | Warren L Gibson R Ishihara L Elango R Xue Z Akkari A Ragone L Pahwa Rajesh Jankovic Joseph Nance Martha Freeman Alan Watts Ray L Hentati F |
| |
Institution: | Research and Development, GlaxoSmithKline Pharmaceuticals, Research Triangle Park, NC 27709, USA. liling.warren@gsk.com |
| |
Abstract: | The Leucine-rich repeat kinase 2 (LRRK2) gene has been identified as a disease susceptibility gene for Parkinson's disease (PD), with G2019 (6055G>A) being the most frequent mutation. This mutation was present in 42% (38/91) of Tunisian families and 2% (1/39) of US families we have studied. A founding haplotype was identified in our data and it is shared by families from Tunisia, US, European and Middle Eastern countries. The most recent common founder of the mutation was dated to 2600 (95% CI: 1950-3850) years ago although additional studies are warranted to ensure an accurate age estimate for this mutation. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|